Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Sarcoma 1

Conditions

Cholangiocarcinoma 2Neoplasm Metastasis 1Gastrointestinal Stromal Tumors 1

Interventions

Specimen Handling 602pembrolizumab 557Magnetic Resonance Spectroscopy 527Carboplatin 422Cyclophosphamide 370Cisplatin 369Biopsy 349Paclitaxel 304Gemcitabine 299Nivolumab 298Radiotherapy 256Bevacizumab 232Dexamethasone 207fludarabine 203Docetaxel 185durvalumab 177atezolizumab 172Oxaliplatin 170Fluorouracil 166venetoclax 164Rituximab 163Pemetrexed 161Doxorubicin 157Radiation 155Capecitabine 155Radiosurgery 145Etoposide 137Leucovorin 133Ipilimumab 132Lenalidomide 129

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × pemigatinib × 90 days × Clear all
NCT07434843 2026-05-22

PEMIGIST

Dana-Farber Cancer Institute

Phase 2 Recruiting
24 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT06302621 2026-05-15

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Massachusetts General Hospital

Phase 1 Recruiting
70 enrolled
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT06728410 2026-05-08

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Hoosier Cancer Research Network

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡